A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide

What this study is testing ClinicalTrials.gov NCT00696657 ↗

Description as written by the study sponsor.

This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment allocation to semaglutide or placebo was double-blind, whereas liraglutide treatment was administered open-label.Primary efficacy parameter was HbA1c and the treatment duration was 12 weeks.

Treatments tested

• semaglutide also known as NN9535 Drug

  0.1 mg, once weekly, s.c. injection

• semaglutide also known as NN9535 Drug

  0.2 mg, once weekly, s.c. injection

• semaglutide also known as NN9535 Drug

  0.4 mg, once weekly, s.c. injection

• semaglutide also known as NN9535 Drug

  0.8 mg, once weekly, s.c. injection

• semaglutide also known as NN9535 Drug

  0.8 mg with titration, once weekly, s.c. injection

• semaglutide also known as NN9535 Drug

  1.6 mg with titration, once weekly, s.c. injection

• placebo Drug

  0.1 mg, once weekly, s.c. injection

• placebo Drug

  0.2 mg, once weekly, s.c. injection

• placebo Drug

  0.4 mg, once weekly, s.c. injection

• placebo Drug

  0.8 mg with titration, once weekly, s.c. injection

• placebo Drug

  1.6 mg, once weekly, s.c. injection

• liraglutide Drug

  1.2 mg with titration, once daily, s.c. injection

• liraglutide Drug

  1.8 mg with titration, once daily, s.c. injection